IP
Ipsen
IPN.PA·EPAParis FRFounded 19295,700 employees
Large CappharmaPublicOncologyRare DiseaseNeurology
Platform: Peptide Bio
Market Cap
$10B
All Drugs
5
Clinical Trials
11
Failed / Terminated
1
FDA Approved
1
Stock Price & Catalysts (IPN.PA)
Loading IPN.PA stock data...
Drug Pipeline (5 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pexaosocimab | IPN-7605 | Phase 2/3 | 2 | C5 | RCC | ||
| Mirirasimod | IPN-4756 | Phase 2 | 1 | SOS1 | RCCCrohn's | ||
| IPN-4133 | IPN-4133 | NDA/BLA | 2 | PI3Kα | NASHWilms | ||
| IPN-129 | IPN-129 | Approved | 4 | PD-L1 | AngelmanWM | ||
| IPN-3758 | IPN-3758 | Phase 1 | 2 | B7-H3 | LGS |
SEC Filings & Financial Documents
SEC filings are not available for EPA-listed companies.
Ipsen trades on EPA (FR). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (8)